A human oral at least partly enteric formulation comprising one or more jojoba components, said formulation being adapted for being human administered up to three times a day or up to three times a week, preferably as a once or twice a day enteric formulation or as a once or twice a week formulation, for use in treating or relieving troubles from patients suffering from a degenerative disease selected from the group consisting of cancer, arthritis, skin disease like psoriasis, alzheimer, parkinson, amyotrophic lateral sclerosis (ALS), Huntington's disease, eye degeneration disease, eye macular degeneration, cornea degeneration, glaucoma and aids and/or for use in treating or relieving troubles from patients suffering from a degenerative skin disease, advantageously selected from the group consisting of psoriasis, acne, hypertrophic lupus erythematosus, basal cell carcinoma and squamous cell carcinoma, by stimulating the p53 gene function for patients suffering from said degenerative disease, or for patients at risk from suffering from said degenerative disease, or for patients under therapeutic treatment of said degenerative disease, and/or by modulating the basic Fibroblast Growth Factor activity and/or the p53 gene function for patients suffering from said degenerative disease, or for patients at risk from suffering from said degenerative disease, or for patients under therapeutic treatment of said degenerative disease, and/or by modulating the angiogenesis effect for patients suffering from said degenerative disease, or for patients at risk from suffering from said degenerative disease, or for patients under therapeutic treatment of said degenerative disease, and/or by controlling the intestinal human microflora, advantageously by inhibition of the development on the intestinal mucosa of bacteria of the group consisting of Salmonella, Listeria, Escherichia Coli, and Staphylococcus, and/or advantageously by stimulating lactic acid bacteria development on the intestine mucosa; * said formulation comprising an effective modulating dose of said one or more jojoba components of less than 1000 mg, advantageously less than 500mg, preferably less than 300mg, most preferably less than 100mg and a sufficient amount of at least one pharmaceutically acceptable excipient for ensuring the release or delivery of at least 75% by weight of the said at least one or more jojoba components in the intestine, preferably in the small intestine tract, the said formulation further comprising at least one enzyme suitable to splice off the glucose moiety of the simmondsin component(s) or jojoba component(s) and/or one or more bacteria suitable for producing one or more enzymes suitable to splice off the glucose moiety of the simmondsin component(s) or jojoba component(s). by stimulating the p53 gene function for patients suffering from said degenerative disease, or for patients at risk from suffering from said degenerative disease, or for patients under therapeutic treatment of said degenerative disease, and/or by modulating the basic Fibroblast Growth Factor activity and/or the p53 gene function for patients suffering from said degenerative disease, or for patients at risk from suffering from said degenerative disease, or for patients under therapeutic treatment of said degenerative disease, and/or by modulating the angiogenesis effect for patients suffering from said degenerative disease, or for patients at risk from suffering from said degenerative disease, or for patients under therapeutic treatment of said degenerative disease, and/or by controlling the intestinal human microflora, advantageously by inhibition of the development on the intestinal mucosa of bacteria of the group consisting of Salmonella, Listeria, Escherichia Coli, and Staphylococcus, and/or advantageously by stimulating lactic acid bacteria development on the intestine mucosa; <EOS>